88 related articles for article (PubMed ID: 19878270)
1. Differential expression of HOXB7 gene in multiple myeloma and extramedullary multiple myeloma patients.
Novak EM; Linardi C; Metzger M; Maria DA; Giorgi RR; Moura F; Martinez GA; Bydlowski SP
Eur J Haematol; 2010 Feb; 84(2):185-6. PubMed ID: 19878270
[No Abstract] [Full Text] [Related]
2. Overexpression of HOXB7 and homeobox genes characterizes multiple myeloma patients lacking the major primary immunoglobulin heavy chain locus translocations.
Agnelli L; Storti P; Todoerti K; Sammarelli G; Dalla Palma B; Bolzoni M; Rocci A; Piazza F; Semenzato G; Palumbo A; Neri A; Giuliani N
Am J Hematol; 2011 Dec; 86(12):E64-6. PubMed ID: 21953534
[TBL] [Abstract][Full Text] [Related]
3. Low expression of ZHX2, but not RCBTB2 or RAN, is associated with poor outcome in multiple myeloma.
Armellini A; Sarasquete ME; García-Sanz R; Chillón MC; Balanzategui A; Alcoceba M; Fuertes M; López R; Hernández JM; Fernández-Calvo J; Sierra M; Megido M; Orfão A; Gutiérrez NC; González M; San Miguel JF
Br J Haematol; 2008 Apr; 141(2):212-5. PubMed ID: 18353163
[TBL] [Abstract][Full Text] [Related]
4. Plasma cell growth fraction using Ki-67 antigen expression identifies a subgroup of multiple myeloma patients displaying short survival within the ISS stage I.
Gastinne T; Leleu X; Duhamel A; Moreau AS; Franck G; Andrieux J; Lai JL; Coiteux V; Yakoub-Agha I; Bauters F; Harousseau JL; Zandecki M; Facon T;
Eur J Haematol; 2007 Oct; 79(4):297-304. PubMed ID: 17692103
[TBL] [Abstract][Full Text] [Related]
5. c-Jun and GST-pi expression in human plasma cells.
Di Simone D; Galimberti S; Mattii L; Petrini M
Haematologica; 1997; 82(1):69-70. PubMed ID: 9107087
[TBL] [Abstract][Full Text] [Related]
6. Using genomics to identify high-risk myeloma after autologous stem cell transplantation.
Shaughnessy JD; Barlogie B
Biol Blood Marrow Transplant; 2006 Jan; 12(1 Suppl 1):77-80. PubMed ID: 16399589
[TBL] [Abstract][Full Text] [Related]
7. The expression of PRDI-BF1 beta isoform in multiple myeloma plasma cells.
Ocaña E; González-García I; Gutiérrez NC; Mora-López F; Brieva JA; Campos-Caro A
Haematologica; 2006 Nov; 91(11):1579-80. PubMed ID: 17043021
[TBL] [Abstract][Full Text] [Related]
8. Lactate dehydrogenase production and release in a newly established human myeloma cell line.
Hatakeyama N; Daibata M; Nemoto Y; Ohtsuki Y; Taguchi H
Am J Hematol; 2001 Apr; 66(4):267-73. PubMed ID: 11279638
[TBL] [Abstract][Full Text] [Related]
9. CD8+ T cells reactive to survivin antigen in patients with multiple myeloma.
Grube M; Moritz S; Obermann EC; Rezvani K; Mackensen A; Andreesen R; Holler E
Clin Cancer Res; 2007 Feb; 13(3):1053-60. PubMed ID: 17289902
[TBL] [Abstract][Full Text] [Related]
10. Insights from the gene expression profiling of multiple myeloma.
Claudio JO; Masih-Khan E; Stewart AK
Curr Hematol Rep; 2004 Jan; 3(1):67-73. PubMed ID: 14695854
[TBL] [Abstract][Full Text] [Related]
11. CD229 Expression on Bone Marrow Plasma Cells from Patients with Multiple Myeloma and Monoclonal Gammopathies of Uncertain Significance.
Carulli G; Buda G; Azzarà A; Ciancia EM; Sammuri P; Domenichini C; Guerri V; Petrini M
Acta Haematol; 2016; 135(1):11-4. PubMed ID: 26303094
[No Abstract] [Full Text] [Related]
12. Induction of integrin beta1 expression in bone marrow cells after chemotherapy correlates with the overexpression of lung resistance protein and poor outcome in patients with multiple myeloma.
Kurata M; Nakagawa Y; Yamamoto K; Suzuki K; Kitagawa M
Am J Hematol; 2008 Sep; 83(9):755-7. PubMed ID: 18615555
[No Abstract] [Full Text] [Related]
13. CD74 is expressed by multiple myeloma and is a promising target for therapy.
Burton JD; Ely S; Reddy PK; Stein R; Gold DV; Cardillo TM; Goldenberg DM
Clin Cancer Res; 2004 Oct; 10(19):6606-11. PubMed ID: 15475450
[TBL] [Abstract][Full Text] [Related]
14. Detection and follow-up of fibroblast growth factor receptor 3 expression on bone marrow and circulating plasma cells by flow cytometry in patients with t(4;14) multiple myeloma.
Chandesris MO; Soulier J; Labaume S; Crinquette A; Repellini L; Chemin K; Malphettes M; Fieschi C; Asli B; Uzunhan Y; Fermand JP; Bories JC; Arnulf B
Br J Haematol; 2007 Feb; 136(4):609-14. PubMed ID: 17223917
[TBL] [Abstract][Full Text] [Related]
15. Bone marrow expression of CCL3 is not correlated with the extent of lytic bone lesions.
Cohen Y; Gutwein O; Garach-Jehoshua O; Bar-Haim A; Kornberg A
Acta Haematol; 2014; 132(2):129-33. PubMed ID: 24556596
[No Abstract] [Full Text] [Related]
16. Dysregulation of CD47 and the ligands thrombospondin 1 and 2 in multiple myeloma.
Rendtlew Danielsen JM; Knudsen LM; Dahl IM; Lodahl M; Rasmussen T
Br J Haematol; 2007 Sep; 138(6):756-60. PubMed ID: 17760807
[TBL] [Abstract][Full Text] [Related]
17. Expression of c-Kit isoforms in multiple myeloma: differences in signaling and drug sensitivity.
Montero JC; López-Pérez R; San Miguel JF; Pandiella A
Haematologica; 2008 Jun; 93(6):851-9. PubMed ID: 18443272
[TBL] [Abstract][Full Text] [Related]
18. Regulation of Bcl-2-family proteins in myeloma cells by three myeloma survival factors: interleukin-6, interferon-alpha and insulin-like growth factor 1.
Jourdan M; De Vos J; Mechti N; Klein B
Cell Death Differ; 2000 Dec; 7(12):1244-52. PubMed ID: 11175262
[TBL] [Abstract][Full Text] [Related]
19. Fibroblast activation protein (FAP) is upregulated in myelomatous bone and supports myeloma cell survival.
Ge Y; Zhan F; Barlogie B; Epstein J; Shaughnessy J; Yaccoby S
Br J Haematol; 2006 Apr; 133(1):83-92. PubMed ID: 16512833
[TBL] [Abstract][Full Text] [Related]
20. Differential expression of vascular endothelial growth factors and their receptors in multiple myeloma.
Kimlinger T; Kline M; Kumar S; Lust J; Witzig T; Rajkumar SV
Haematologica; 2006 Aug; 91(8):1033-40. PubMed ID: 16870555
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
